- Conditions
- Anal Cancer
- Interventions
- cetuximab, cisplatin, fluorouracil, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 7
- States / cities
- La Jolla, California • Los Angeles, California • Boston, Massachusetts + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 2,290
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
- Interventions
- E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
- Biological · Drug · Diagnostic Test + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • New Brunswick, New Jersey
- Conditions
- Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
- Interventions
- MT-8421, Nivolumab
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more
- Conditions
- Head and Neck Carcinoma, Head and Neck Lymph Node, Head and Neck Squamous Cell Carcinoma, Laryngeal Neoplasm, Radiation Therapy Recipient
- Interventions
- Photoacoustic Imaging, Transcutaneous Acupoint Electrical Stimulation
- Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
- Interventions
- erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies, gene expression analysis, 3-dimensional conformal radiation therapy, biopsy, pharmacological study, laboratory biomarker analysis, questionnaire administration, enzyme-linked immunosorbent assay, polymorphism analysis
- Drug · Radiation · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer
- Interventions
- Sacituzumab Govitecan-hziy (SG)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more
- Conditions
- Esophagus Cancer, Esophageal Cancer, Esophageal Neoplasms, Esophageal Diseases, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophagus SCC, Esophagus Tumor, Esophagus Adenocarcinoma, Esophagus Neoplasm
- Interventions
- ActivSight
- Device
- Lead sponsor
- Activ Surgical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Nelfinavir (Viracept®) 1250 mg, Chemoradiation
- Drug · Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer
- Interventions
- Durvalumab, Carboplatin, Nab-paclitaxel, Cisplatin, Surgical resection, IMRT
- Drug · Procedure · Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Nashville, Tennessee
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
- Interventions
- ASP-1929 Photoimmunotherapy
- Combination Product
- Lead sponsor
- Rakuten Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cervical Cancer
- Interventions
- 64Cu-ATSM, FDG
- Drug
- Lead sponsor
- American College of Radiology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Los Angeles, California • St Louis, Missouri
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Carcinoma in the Skin, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Kidney Biopsy, Magnetic Resonance Imaging, Nivolumab, Prednisone, Sirolimus
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 26
- States / cities
- La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
- Interventions
- NBTXR3, SABR, Nivolumab, Pembrolizumab
- Drug · Radiation
- Lead sponsor
- Nanobiotix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 13
- States / cities
- San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more
- Conditions
- Aerodigestive Precancerous Lesions and Malignancies
- Interventions
- INO-3106, INO-9012
- Biological
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Cetuximab, Stereotactic radiosurgery
- Drug · Device
- Lead sponsor
- David A. Clump, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Head and Neck Cancer, Lung Cancer
- Interventions
- filgrastim, cisplatin, paclitaxel, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 18
- States / cities
- Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 15 more
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Pembrolizumab (immunotherapy), Quad-shot palliative radiotherapy
- Drug · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Head and Neck Cancer
- Interventions
- blood-oxygen-level-dependent functional magnetic resonance imaging, diffusion tensor imaging, dynamic contrast-enhanced magnetic resonance imaging, functional magnetic resonance imaging, intensity-modulated radiation therapy, radiation therapy treatment planning/simulation
- Procedure · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Squamous Cell Carcinoma Of The Head And Neck
- Interventions
- Cetuximab, Dasatinib
- Drug
- Lead sponsor
- Julie E. Bauman, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Head and Neck Cancer
- Interventions
- medical chart review
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Head and Neck Cancer
- Interventions
- Erlotinib
- Drug
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
- Interventions
- Panitumumab, Talimogene Laherparepvec
- Biological
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 5
- States / cities
- New Brunswick, New Jersey • New York, New York • Durham, North Carolina
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, Radiotherapy, ENI, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Lymphedema, Stage IA1 Cervical Cancer AJCC v6 and v7, Stage IA2 Cervical Cancer AJCC v6 and v7, Stage IB1 Cervical Cancer AJCC v6 and v7
- Interventions
- Conization, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery, Therapeutic Lymphadenectomy
- Procedure · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 174
- States / cities
- Phoenix, Arizona • Auburn, California • Berkeley, California + 136 more